NCT04748042View on ClinicalTrials.gov

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate CancerCastrate Sensitive Prostate CancerOligometastatic Disease
Interventions
DRUG

Abiraterone

Abiraterone 1000 mg by mouth per day for approximately 6 months.

DRUG

Prednisone

Prednisone 5 mg by mouth per day for approximately 6 months.

RADIATION

External Beam Radiotherapy

External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.

BIOLOGICAL

Androgen Deprivation Therapy (ADT)

ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.

DRUG

Olaparib

Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.

Trial Locations (1)

48109

University of Michigan Rogel Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER